Document is current
Any future updates will be listed below
-
Authors
Kim, Hyun J.
Snyder, Laurie D.
Adegunsoye, Ayodeji
Neely, Megan L.
Bender, Shaun
White, Eric S.
Conoscenti, Craig S.
Strek, Mary E.
Baker, Albert
Beegle, Scott
Belperio, John A.
Condos, Rany
Cordova, Francis
Culver, Daniel A.
Dilling, Daniel
Fitzgerald, John
Silhan, Leann
Flaherty, Kevin R.
Gibson, Kevin
Gulati, Mridu
Guntupalli, Kalpalatha
Gupta, Nishant
Hajari Case, Amy
Hotchkin, David
Huie, Tristan J.
Kaner, Robert J.
Kim, Hyun J.
Lancaster, Lisa H.
Steele, Mark
Lasky, Joseph A.
Lee, Doug
Liesching, Timothy
Lipchik, Randolph
Lobo, Jason
Luckhardt, Tracy R.
Andrade, Joao A.
Mageto, Yolanda
Huang, Howard
Menon, Prema
Mageto, Yolanda
Morrison, Lake
Namen, Andrew
Oldham, Justin M.
Paul, Tessy
Zhang, David
Podolanczuk, Anna
Lederer, David
Patel, Nina M.
Porteous, Mary
Kreider, Maryl
Raj, Rishi
Mohabir, Paul
Ramaswamy, Murali
Russell, Tonya
Sachs, Paul
Safdar, Zeenat
Shafazand, Shirin
Glassberg, Marilyn
Siddiqi, Ather
Asi, Wael
Sigal, Barry
Strek, Mary E.
Noth, Imre
Suliman, Sally
Roman, Jesse
Tabak, Jeremy
Walia, Rajat
Whelan, Timothy P. M.
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01915511 at ClinicalTrials.govDocuments that mention this clinical trial
Hospitalizations in patients with idiopathic pulmonary fibrosis
https://doi.org/10.1186/s12931-021-01851-4
Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
https://doi.org/10.1007/s00408-021-00506-x
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
https://doi.org/10.1186/s12931-021-01921-7
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
https://doi.org/10.1136/bmjresp-2020-000567
-
Funding
Funding for this research was provided by:
The IPF-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co-ordinated by the Duke Clinical Research Institute (DCRI).
- License Information
-
More Information
Article History
Received: 6 May 2021
Accepted: 23 September 2021
First Online: 30 September 2021
Declarations
:
: The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was also approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at each site listed in the Acknowledgments. All patients provided informed consent.
: Not applicable.
: HJK is a member of the Publication Committee for the IPF-PRO/ILD-PRO Registry. LDS and MLN are faculty members in the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to co-ordinate the IPF-PRO/ILD-PRO Registry. AA reports grants and personal fees from Boehringer Ingelheim, personal fees from Genentech and grants from the Pulmonary Fibrosis Foundation and the National Institutes of Health. SB, ESW and CSC are employees of Boehringer Ingelheim Pharmaceuticals, Inc. MES reports grants, personal fees and non-financial support from Boehringer Ingelheim; grants from Galapagos; and personal fees from FibroGen.
